File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Identification of microrna-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma

TitleIdentification of microrna-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma
Authors
Issue Date2014
Citation
Clinical Cancer Research, 2014, v. 20, n. 11, p. 2994-3002 How to Cite?
AbstractPurpose: Detecting microRNA (miRNA) in stool is a novel approach for colorectal cancer (CRC) screening. This study aimed to identify stool-based miRNA as noninvasive biomarkers for detection of CRC and adenoma. Experimental Design: A miRNA expression array covering 667 human miRNAs was performed on five pairs of CRC and two pairs of advanced adenoma tissues. The most upregulated miRNAs were validated in 40 pairs of CRC tissues, 16 pairs of advanced adenoma tissues, and 424 stool samples, including 104 CRCs, 169 adenomas, 42 inflammatory bowel diseases (IBD), and 109 healthy controls. miRNA levels were followed-up after removal of lesions. Results: In an array analysis, miR-31 and miR-135b were the most upregulated miRNAs in CRC and advanced adenoma as compared with their adjacent normal tissues (>13-fold increase). In stool samples, level of miR-135b was significantly higher in subjects with CRC (P < 0.0001) or adenomas (P < 0.0001), but not in patients with IBD compared with controls. miR-135b showed a significant increasing trend across the adenoma to cancer sequence (P < 0.0001). Levels of miR-31 were not significantly different among groups. The sensitivity of stool mR-135b was 78% for CRC, 73% for advanced adenoma, and 65% for any adenoma, respectively, with a specificity of 68%. No significant difference in the miR-135b level was found between proximal and distal colorectal lesions. Stool miR-135b dropped significantly upon removal of CRC or advanced adenoma (P < 0.0001). Conclusion: Stool-based miR-135b can be used as a noninvasive biomarker for the detection of CRC and advanced adenoma. ©2014 AACR.
Persistent Identifierhttp://hdl.handle.net/10722/207126
ISSN
2015 Impact Factor: 8.738
2015 SCImago Journal Rankings: 5.314

 

DC FieldValueLanguage
dc.contributor.authorWu, Chungwah-
dc.contributor.authorNg, Siewchien-
dc.contributor.authorDong, Yujuan-
dc.contributor.authorTian, Linwei-
dc.contributor.authorNg, Simon Siu Man-
dc.contributor.authorLeung, Wingwa-
dc.contributor.authorLaw, Waitak-
dc.contributor.authorYau, Tungon-
dc.contributor.authorChan, Francis Ka Leung-
dc.contributor.authorSung, Joseph-
dc.contributor.authorYu, Jun-
dc.date.accessioned2014-12-09T04:31:27Z-
dc.date.available2014-12-09T04:31:27Z-
dc.date.issued2014-
dc.identifier.citationClinical Cancer Research, 2014, v. 20, n. 11, p. 2994-3002-
dc.identifier.issn1078-0432-
dc.identifier.urihttp://hdl.handle.net/10722/207126-
dc.description.abstractPurpose: Detecting microRNA (miRNA) in stool is a novel approach for colorectal cancer (CRC) screening. This study aimed to identify stool-based miRNA as noninvasive biomarkers for detection of CRC and adenoma. Experimental Design: A miRNA expression array covering 667 human miRNAs was performed on five pairs of CRC and two pairs of advanced adenoma tissues. The most upregulated miRNAs were validated in 40 pairs of CRC tissues, 16 pairs of advanced adenoma tissues, and 424 stool samples, including 104 CRCs, 169 adenomas, 42 inflammatory bowel diseases (IBD), and 109 healthy controls. miRNA levels were followed-up after removal of lesions. Results: In an array analysis, miR-31 and miR-135b were the most upregulated miRNAs in CRC and advanced adenoma as compared with their adjacent normal tissues (>13-fold increase). In stool samples, level of miR-135b was significantly higher in subjects with CRC (P < 0.0001) or adenomas (P < 0.0001), but not in patients with IBD compared with controls. miR-135b showed a significant increasing trend across the adenoma to cancer sequence (P < 0.0001). Levels of miR-31 were not significantly different among groups. The sensitivity of stool mR-135b was 78% for CRC, 73% for advanced adenoma, and 65% for any adenoma, respectively, with a specificity of 68%. No significant difference in the miR-135b level was found between proximal and distal colorectal lesions. Stool miR-135b dropped significantly upon removal of CRC or advanced adenoma (P < 0.0001). Conclusion: Stool-based miR-135b can be used as a noninvasive biomarker for the detection of CRC and advanced adenoma. ©2014 AACR.-
dc.languageeng-
dc.relation.ispartofClinical Cancer Research-
dc.titleIdentification of microrna-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/1078-0432.CCR-13-1750-
dc.identifier.scopuseid_2-s2.0-84901793311-
dc.identifier.volume20-
dc.identifier.issue11-
dc.identifier.spage2994-
dc.identifier.epage3002-
dc.identifier.eissn1557-3265-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats